Upregulated LINC00565 Accelerates Ovarian Cancer Progression by Targeting GAS6 [Corrigendum]

Gong M, Luo C, Meng H, et al. Upregulated LINC00565 accelerates ovarian cancer progression by targeting GAS6. *OncoTargets Ther.* 2019;12:10011–10022.

Upon reviewing the article, the authors noticed an error in Figure 5D on page 10019, it should be presented as follows:

The authors confirm that all of the results and conclusions of the article remain unchanged. The authors apologize for this error.

Figure 5 LINC00565 regulates the tumor growth in vivo. **(A)** The growth of tumors from sh-LINC00565 group were markedly slower than these from sh-NC group. **(B)** The tumors dissected from sh-LINC00565 group node mice were lighter than the sh-NC group. **(C)** qRT-PCR verified that LINC00565 expression was lower in sh-LINC00565 group than that in sh-NC group. **(D)** Immunohistochemistry showed that PCNA, Ki-67, Cyclin D1, Cyclin E1 and CDK4 were markedly reduced in LINC00565 knockdown group compared with NC group, nevertheless, P16 and P21 showed the opposite effect. *** $P < 0.001$.

OncoTargets and Therapy**Dovepress****Publish your work in this journal**

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>